New drug after transplant shows promise in reducing deadly complications
NCT ID NCT01349101
First seen Jan 10, 2026 · Last updated Apr 30, 2026 · Updated 19 times
Summary
This study looked at whether giving the drug cyclophosphamide after a stem cell transplant can help the new cells settle in better and lower the risk of graft-versus-host disease (GVHD), a serious complication. It involved 78 people with blood cancers who received a transplant from a related or unrelated donor. The goal was to make alternative donor transplants as safe and effective as traditional matched ones.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.